Ocugen (OCGN) Non Operating Income (2014 - 2026)
Ocugen's (OCGN) quarterly Non Operating Income came in at -$1.3 million in Q1 2026, down 57.6% YoY from -$3.2 million in Q1 2025, and down 88.19% on a QoQ basis from -$711000.0 in Q4 2025.
Ocugen (OCGN) Non Operating Income (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Non Operating Income data on file, last reported at -$1.3 million in Q1 2026.
- Quarterly Non Operating Income fell 57.6% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.4 million (down 613.75% YoY) and the FY2025 annual result came in at -$4.9 million, down 801.28% from the prior year.
- Non Operating Income declined to -$1.3 million in Q1 2026, from -$711000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.2 million in Q3 2022 to a low of -$2.4 million in Q3 2025.
- A 5-year average of -$15411.8 and a median of $94000.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 10777.78% — and 2025, when it sank 8390.0%.
- Tracing OCGN's Non Operating Income over 5 years: stood at $961000.0 in 2022, then tumbled by 42.25% to $555000.0 in 2023, then slumped by 107.21% to -$40000.0 in 2024, then slumped by 1677.5% to -$711000.0 in 2025, then slumped by 88.19% to -$1.3 million in 2026.
- The last three Non Operating Income figures came in at -$1.3 million (Q1 2026), -$711000.0 (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | -8.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.43 Mn |
| Mar 31, 2026 | -1.34 Mn |
| Dec 31, 2025 | -711,000.00 |
| Sep 30, 2025 | -2.43 Mn |
| Jun 30, 2025 | 114,000.00 |
| Mar 31, 2025 | -849,000.00 |
| Dec 31, 2024 | -40,000.00 |
| Sep 30, 2024 | 282,000.00 |
| Jun 30, 2024 | -4,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | 555,000.00 |
| Sep 30, 2023 | 714,000.00 |
| Jun 30, 2023 | 475,000.00 |
| Mar 31, 2023 | 709,000.00 |
| Dec 31, 2022 | 961,000.00 |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 94,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | -9,000.00 |
| Sep 30, 2021 | -18,000.00 |